3.8 Review

Current imaging modalities for atherosclerosis

期刊

EXPERT REVIEW OF CARDIOVASCULAR THERAPY
卷 10, 期 4, 页码 457-471

出版社

TAYLOR & FRANCIS INC
DOI: 10.1586/ERC.12.28

关键词

anti-atherosclerotic medical therapies; atheroma progression; atheroma regression; atherosclerosis; imaging modalities

资金

  1. AstraZeneca
  2. Pfizer
  3. Merck Schering-Plough
  4. Takeda
  5. Roche
  6. NovoNordisk
  7. LipoScience
  8. Anthera
  9. Lipid Sciences

向作者/读者索取更多资源

Atherosclerotic disease is responsible for nearly half of all deaths in the western world. During the past three decades, considerable efforts have been made towards detection and assessment of atherosclerosis plaques in various vascular beds using different imaging techniques. Recently, both noninvasive and invasive modalities have frequently been used to refine cardiovascular risk assessment in high-risk individuals, to evaluate the natural history of atheroma burden and to reveal the impact of anti-atherosclerotic medical therapies on disease progression. In this review, we provide an overview of the currently available imaging modalities. This article will underscore arterial wall imaging to assess the impact of medical therapies on atherosclerosis and to develop the effective therapeutic strategies, resulting in the prevention of cardiovascular complications.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

3.8
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据